One shot to rule them all? new combo meningitis vaccine tested in teens
NCT ID NCT05087056
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new vaccine called MenABCWY that aims to protect against five types of meningococcal bacteria, which can cause serious infections like meningitis. Around 312 healthy teenagers will receive two doses of the vaccine on different schedules to see how safe it is and how well it triggers the immune system. The goal is to find a convenient way to protect against multiple strains with fewer shots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MenABCWY vaccine (combined meningococcal groups A, B, C, W, Y)
What this could lead to
If successful, this could lead to a single vaccine that protects against five major types of meningococcal disease, simplifying vaccination schedules for teens.
What could go wrong
This is a mid-stage trial with only 312 participants, so results may not apply to everyone. The vaccine may cause side effects like pain or fever, and it's not yet proven to prevent disease in the real world.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS, MENINGOCOCCAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Tucson, Arizona, 85745, United States
-
GSK Investigational Site
Ventura, California, 93003, United States
-
GSK Investigational Site
Macon, Georgia, 31210, United States
-
GSK Investigational Site
Valparaiso, Indiana, 84088, United States
-
GSK Investigational Site
Missoula, Montana, 80216, United States
-
GSK Investigational Site
Charlotte, North Carolina, 28226, United States